Slivnick JA, et al. - Recent studies have shown harm associated with peri-procedural bridging using low-molecular-weight heparin (LMWH) for warfarin-treated patients with Atrial Fibrillation (AF) at low thromboembolic risk. Bridging in the setting of gastrointestinal endoscopy was retrospectively assessed herein, to gain an insight into current trends in anticoagulation bridging in these patient populations. Findings showed that patients with AF on warfarin received excessive LMWH bridging in the setting of endoscopy. Furthermore, among cardiologists, lower rates of bridging were observed, suggesting a need for their increased involvement in this decision-making.